An assessment of injection site reaction and injection site pain of 1‐month and 3‐month long‐acting injectable formulations of paliperidone palmitate. Issue 4 (14th February 2018)

• Record Type: Journal Article
• Authors: Kern Sliwa, Jennifer; Savitz, Adam; Nuamah, Isaac; Mathews, Maju; Gopal, Srihari; Elefant, Erica; Najarian, Dean; Alphs, Larry
• Is Part Of: Perspectives in psychiatric care. Volume 54:Issue 4(2018:Oct.)
• Page Start: 530
• Page End: 538
• Publication Date: 2018-02-14
• Subjects: injection site pain -- injection site reaction -- injection site volume -- paliperidone palmitate 1‐monthly -- paliperidone palmitate 3‐monthly -- schizophrenia -- visual analog scale score; Psychiatric nursing -- Periodicals; Psychiatric nursing -- Research -- Periodicals; 616.890231
• DOI: 10.1111/ppc.12267
• Languages: English
• ISSNs: 0031-5990

Abstract

Abstract: Purpose: To evaluate injection site reactions and pain following paliperidone palmitate 1‐month (PP1M) and 3‐month (PP3M) administration using safety data of double‐blind (DB), noninferiority study. Methods: Patients ( n = 1, 429) with schizophrenia, treated with PP1M (50–150 mg‐eq, 17‐week open‐label [OL] phase) were randomized to PP1M or PP3M in 48‐week DB phase. Findings: PP1M and PP3M injections were well tolerated. Incidence of induration, redness, and swelling were low in both phases (OL: 9–12%; DB: 7–13%), and were mostly mild in both groups. Mean ( SD ) visual analog scale scores decreased from OL‐baseline (22.0 [21.6]) to DB‐baseline (19.5 [20.6] vs. 18.4 [20.4]) and DB‐endpoint (15.6 [17.9] vs. 15.5 [18.3]). Practice Implications: Injection site reactions and pain were low and similar between both treatments, regardless of administration site and dose.